Uncategorized

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists also show potential in several other indications, including cancer, addiction and neurodegenerative diseases.

Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric low-grade glioma. Geron Corporation and ImmunityBio also notched wins.

Las apuestas de eSports son una combinación de estrategia, adrenalina y la posibilidad de ganar dinero. Sin embargo, es más desafiante que ser fanático de un equipo determinado. También es muy competitivo e impredecible en el espacio digital en cuanto al siguiente movimie …

Edwards submitted a request for a national coverage determination in February, after receiving FDA approval for its Evoque device earlier that month.

Inspectors found 111 open tickets for software defects categorized as catastrophic or severe patient harm. Several safety complaints were also listed that BD didn’t report within the required timeframe.

IPOs in medtech have been sparse, but some analysts said improving market conditions could support a revival of offerings in 2025.

Novo Nordisk executives set a high bar for itself when it projected CagriSema could achieve 25% weight loss. When the GLP-1 combo didn’t hit that mark, investors reeled.

From challenging market leaders to the growing influence of artificial intelligence, medical device executives had a lot to discuss this year. Check out MedTech Dive’s top Q&As of 2024.

Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint for its Phase IIb/III trial for patients with a type of liver cirrhosis.

The breach is the third largest reported to a portal managed by federal regulators this year.